management program, only 14,3% patients with an indication for preventive treatment visited their GP and only 14% started with CV risk lowering drugs. This is mainly caused by the small percentage of high risk patients that contacted their GP. On the other hand, a high percentage reported the start of healthy lifestyle. These results underscore the need for a short-term follow-up, in close collaboration with primary care providers to ensure appropriate CV risk management. This is a future implementation project that will be initiated shortly. Background: RA patients have a higher risk for developing CV Diseases (e.g. IHD and stroke) than the general population.We reported previously (ACR, EULAR) the results CV risk in our patients treated with bDMARDs for 1& 2 years. Objectives: To assess the effect of bDMARDs treatment on 10-year CV disease risk in patients with RA after 36 months and evaluate the impact of their use on the incidence of CV events Methods: A cohort of RA patients was followed prospectively.Demographics, disease activity parameters, inflammatory markers, CV events, CVD 10 year risk assessment [Framingham Risk Score (FRS) ] were ascertained at the baseline and every six months, up to 36 months.Statistical analysis utilized SPSS (IBM version 24) software. Results: 321 patients were included, of those 270 patients were followed for three years. Eight BDMARDs were included evaluating their effect on disease activity and CV risk in 233 patients who continued on their prospective biologic for the three years. Significant overall reduction in disease activity in all groups was obtained as compared to baseline. The whole group DAS improved from 3.996 to 3.118.
The HAQ also improved significantly (1.201 to 0.857) and the CRP improved significantly (12.91 mg/L to 7.3). Overall, Total cholesterol (TC) changed from 5.195 mmol/L at baseline to 4.992 (P 0.001). High Density Lipoprotein Cholesterol (HDL-C) increased significantly at 36 months from 1.336 to 1.376. However, the Atherogenic Index (AI) for the whole cohort changed from 3.636 to 3.845. The overall 10 year risk of cardiovascular event increased from 12.878 to 13.8 The cohort included 321 patients. Eight bDMARDs were evaluated to assess their effect on disease activity and CVD risk. The outcomes in 233 patients who continued their prospective biologic for the three years were reported (table). 77% were females, median RA duration was 11 ys. Significant reduction in disease activity in all groups was achieved vs. baseline. The DAS improved from 3.996 to 3.118, the HAQ improved significantly (1.201 to 0.857) and the CRP also improved significantly (12.91 mg/L to7.3). Overall, Total cholesterol (TC) changed from 5.195 mmol/L at baseline to 4.992 (P 0.001). High Density Lipoprotein Cholesterol (HDL-C) increased significantly at 36 months from 1.336 to 1.376. The Atherogenic Index (AI) for the cohort changed from 3.636 to 3.845. The overall 10 year risk of cardiovascular event increased from12.878 to 13.8. Background: Pain in patients with rheumatoid arthritis (RA) is the most common and troublesome symptom, occurs frequently in many sites in the muscularskeletal system, causes fatigue and functional impairment. The origin of pain in RA may be inflammatory and/or other, such as increased sensitivity to pain, fibromyalgia and osteoarthritis. Objectives: To study unacceptable pain in an inception cohort of patients with RA at 15 years follow-up Methods: This study concerns 477 patients from the BARFOT inception cohort study, consisting of 839 patients with early RA, who have passed the pre-defined 15 year follow-up visit. Unacceptable pain (UP) was defined as ≥40 mm on a continuous VAS pain scale of 100 mm with the ends "no pain" and "worst possible pain" (1). ADL-function was assessed by the HAQ test, physical function by the SOFI test and joint damage by the van der Heijde modified Sharp method. Remission was defined as DAS28 ≤2.6. The prevalence of UP over time as well as the relationship of UP with clinical variables were assessed. Baseline predictors of UP after 15 years were evaluated by logistic regression. Results: The mean baseline VAS pain was 45 mm, decreased after 6 months to 29 and remained after that fairly stable through the years ending in 31 at 15 years. UP followed a similar course with 56% of the patients at baseline, which decreased to 30% after 6 months and then behaved stable until 15 years, 34%. Seventy-seven per cent of the patients with UP were not in remission at 15 years, while 23% had UP in spite of being in remission.
Patients with UP who were in remission at the 15 years visit had higher mean age (p=0.004), ESR (p=0.001) and SOFI (p=0.001) than patients without UP.
Patients with UP who were not in remission at this point in time were more often women (0.008) and had more tender joints (p=0.001) than patients who did not have UP.
In both remission groups the mean DAS28, patient global assessment and HAQ were higher in patients with UP compared with patients without.
The means of the x-ray joint damage scores -total score, erosion and joint space narrowing scores -were very similar among patients with or without UP, statistically not significant. A logistic regression analysis of the ability of baseline variables to predict UP at 15 years was performed. It was shown that female gender and baseline pain independently predicted unacceptable pain at 15 years in patients not in remission while in patients in remission high age and ESR were independent predictors.
Conclusions:
Pain is a frequent and relentless suffering during the long-term course of rheumatoid arthritis. In this study, 34% of the patients had unacceptable pain 15 years after diagnosis indicating unsatisfactory treatment. Unacceptable pain also occurred in patients in remission indicating that pain in RA is multifactorial. Therefore, the cause of pain should be identified and treatment initiated accordingly. Background: The use of anti-tumor necrosis factor-alpha agents, or anti-TNFs, has greatly improved the treatment of rheumatoid arthritis (RA). The first three anti-TNFs available to us (infliximab, adalimumab, and etanercept) are the most widely used in treating RA. Their efficacy and safety, demonstrated in extensive randomized and controlled trials (RCTs), were not shown to vary significantly when compared indirectly based on randomized studies. Nevertheless, the randomized studies were of short duration and included a selected population that differed from patients treated in daily practice. Background: Corticosteroids are often used for treating rheumatoid arthritis. However, minimizing adverse events while maximizing efficacy remains challenging. An alternate-day corticosteroid dose is known to decrease adverse events. Objectives: To investigate the safety and efficacy of an alternate-day corticosteroid dose for treating rheumatoid arthritis. Methods: We have conducted a retrospective cohort study among patients over 18-year-old who started oral corticosteroids (prednisolone and methylprednisolone) as treatment of rheumatoid arthritis from 2005 to 2014 at St. Luke's International Hospital, a tertiary-level community teaching hospital in Tokyo, Japan. Patients were included if they met the American College of Rheumatology/European League Against Rheumatism 2010 classification criteria for rheumatoid arthritis, and had positive anti-cyclic citrullinated peptide antibody. They were excluded for a history of corticosteroid use for other diseases, or if they were lost to follow-up within 1 year after starting corticosteroids. We divided patients into a daily corticosteroid group (QD) and an alternate-day corticosteroid group (QOD). Patients who received both daily and alternate-day corticosteroids were assigned to the daily group. We investigated the percentage of patients without any infection within 1 year after starting corticosteroids. We have conducted multivariate logistic regression model analysis to calculate adjusted odds ratio for QD/QOD to the outcome. We also investigated the mean decrease in C-reactive protein (CRP) at 1 month as a marker of short-term effectiveness, and the percentage of patients free from corticosteroid at one year, using student's t-test. Results: In total, 139 patients were analysed (69 in the QD group, 70 in the QOD group). The maximum dose of corticosteroid in one year was not significantly different in two groups (11.4±7.7 mg/day VS 10.1±5.3 mg/day; P=0.267), and the mean daily dose of corticosteroid in one year was significantly higher in the QD group (6.1±4.4 mg/day vs 3.9±1.7 mg/day; P<0.01).The percentage of patients without any infection was 49.2% in QD group, and 75.7% in QOD group. Univariate analysis showed QD group is significantly associated with higher incidence of infection (P=0.001). After multivariate analysis adjusted with age, gender, initial CRP value, mean daily dose of corticosteroid in one year, use of biologic DMARDs, and duration of rheumatoid arthritis, the odds ratio of QD for any infection in 1 year was 3.9 (95% confidence interval [CI], 1.7-8.8; P=0.001).The mean decrease of CRP at 1 month was 1.5 mg/dl in QD group, and 1.1 mg/dl in QOD group (P=0.435).The percentage of patients free from corticosteroids at one year was 26.1% in QD group, and 58.6% in QOD group (P<0.01). Kaplan-Meier plot showed that QD group patients are more difficult to become free from corticosteroid (log-rank test: p<0.01).
Conclusions: Alternate-day corticosteroid dose has a lower adverse event rate and is as effective as a daily corticosteroid dose for treating rheumatoid arthritis. Background: Prior studies have suggested higher rates of preterm birth in pregnancies to women with rheumatoid arthritis. Objectives: We sought to identify differences in the pregnancy outcomes of women with and without RA, and pregnancies that occurred prior to and following RA diagnosis. Methods: A cross-sectional survey was completed by 75 women with RA age-matched to 75 women without RA. Information collected about each prior pregnancy included: pregnancy outcome (spontaneous abortion, stillbirth, elective termination, ectopic pregnancy, or live birth); the timing of delivery; infant anomalies; methotrexate exposure in pregnancy; and whether the pregnancy was planned. Simple statistics were used to compare pregnancy outcomes between women with and without RA and pregnancies prior to and following RA diagnosis. Results: The majority of women with RA (83%) and controls (64%) were white, and 11% of women with RA and 28% of controls were African American. About half of controls and 31% of women with RA had education beyond college. The average age at the time of the survey was 32 years (SD: 5) in both RA patients and controls, and the average age at RA diagnosis was 23 years (SD: 10). There were 76 pregnancies in 40 women with RA and 99 pregnancies in 33 healthy controls (see table) . The overall rates of live birth, spontaneous abortion, and ectopic pregnancies were similar between groups; there were no stillbirths. The rate of elective termination was significantly different, with 9% of RA and 30% of control pregnancies terminated (p=0.005). The large majority of the terminations in women with RA occurred prior to diagnosis. The higher frequency of unplanned pregnancy among the controls (38% unplanned RA vs 67% unplanned controls, p=0.0002) likely contributed to this higher termination rate. Of unplanned pregnancies, 45% were terminated in controls, 33% in pre-RA pregnancies, and 9% in post-RA pregnancies. No planned pregnancies were terminated. Three pregnancies in women with RA were exposed to methotrexate (2 unplanned, 1 planned) resulting in 2 spontaneous abortions and 1 live birth, born at term without any reported abnormalities. The rates of preterm birth and infant abnormalities did not differ significantly between those with and without RA, though among women with RA, all preterm births and infant abnormalities occurred after RA diagnosis. Each of the RA preterm births was delivered between 31-34 weeks gestation. Preeclampsia
